[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577030":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":60,"collaborators":62,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":10,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"German CLL Study Group","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patienst with CLL who received at least firstline treatment within a clinical trial",null,"This trial will enroll patients who received first-line treatment in either CLL13, CLL14, or CLL17 trial. On ground of feasibility the sample size of the study is estimated at approximately 1800-2100 patients in total. No formal sample size calculation has been performed",[13],"Other: Observational",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational","The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively",[9],[20],{"name":21,"affiliation":22,"role":23},"BArbara F. Eichhorst, MD","Uniklinik Köln","STUDY_CHAIR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":28,"email":29},"Kirsten Fischer, MD","CONTACT","+4922147888220","kirsten.fischer@uk-koeln.de",{"name":31,"role":27,"phone":28,"phoneExt":28,"email":32},"Aline Zey, Dipl.Biol.","aline.zey@uk-koeln.de",[34,51],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University Hospital Cologne","RECRUITING","Cologne","50924","Germany","DE",{"type":42,"coordinates":43},"Point",[44,45],6.95,50.93333,{"lat":45,"lon":44},[48],{"name":49,"role":27,"phone":28,"phoneExt":28,"email":50},"NAdine Kutsch, MD","nadine.kutsch@uk-koeln.de",{"facility":52,"status":36,"city":53,"state":10,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":59,"contacts":10},"Universitätsklinikum Ulm","Ulm","89081",{"type":42,"coordinates":56},[57,58],9.99155,48.39841,{"lat":58,"lon":57},{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[63,65,68,70],{"name":64,"class":6},"GELLC (Grupo Español de Leucemia Linfocítica Crónica)",{"name":66,"class":67},"Nordic Lymphoma Group","NETWORK",{"name":69,"class":6},"Polish Adult Leukemia Group",{"name":71,"class":6},"HOVON - Dutch Haemato-Oncology Association","100577030","a-prospective-observational-trial-to-assess-treatment-sequences-and-factors-that-impact-overall-sur-vival-in-patients-with-chronic-lymphocytic-leukaemia-cll-treated-within-first-line-studies-of-the-gcllsg-100577030",false,"NCT06792994","A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG","CLL2000","Inclusion Criteria:\n\n* • Subjects must voluntarily sign and date an informed consent, ap-proved by an independent ethics committee (IEC)\u002Finstitutional review board (IRB)\n\n  * Documented diagnosis of CLL at time point of inclusion in a first-line study of the GCLLSG (development of RT is not an exclusion criterion)\n  * First-line treatment was administered within one of these first-line studies of the GCLLSG (CLL13, CLL14, or CLL17).\n  * Subsequent therapy lines were either documented during the participa-tion in a first-line study of the GCLLSG or patient consented to have the subsequent therapy lines documented within this observational trial.\n  * Subjects are willing and able to comply with procedures required in this protocol.\n\nExclusion Criteria:\n\n* • Patients without participation in one of the first-line studies of the GCLLSG (CLL13, CLL14, CLL17)\n\n  * Subjects with legal incapacity\n  * Subjects who are institutionalized by regulatory or court order\n  * Subjects who are in dependence to the sponsor or the investigator","ALL","18 Years","99 Years",{"count":83,"type":84},2000,"ESTIMATED","OBSERVATIONAL","This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.",[88],"Chronic Lymphocytic Leukemia",[90],"Long-term observation, CLL","2026-04-27",{"date":93,"type":94},"2026-04-30","ACTUAL",{"date":96,"type":94},"2026-04-02",{"date":98,"type":84},"2030-08-01",{"name":5,"class":6},2]